ClinicalTrials.gg
Active, not recruitingNCT05092347Updated Jun 2, 2026

A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)

A Phase 1/2 interventional study of Vonsetamig in Chronic Kidney Disease (CKD), sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 10 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by Regeneron Pharmaceuticals · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 988 studies in Renal Insufficiency, Chronic with a site in United States — 170 open to participants now, 218 under way, 25 of them phase 3. Renal Insufficiency, Chronic · United States.

Enrollment
507th of 819
43 · median 72
Started
2022
with 56 others
Phase 1/2
16 of 988
6 open now
Primary completion
2027-11
later than 115 of 216 live
Registered
723rd of 988
by date

Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, this one is the 507th largest by enrollment of the 819 interventional ones that give a count, is one of 57 that started in 2022, is one of 16 in phase 1/2, reaches primary completion later than 115 of the 216 other live ones, and was the 723rd registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

170 of the 988 studies in Renal Insufficiency, Chronic with a site in United States are open now. Recruiting first, the newest first:

165 more — sign in →

All 170 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 988 studies in Renal Insufficiency, Chronic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether vonsetamig will safely decrease anti-HLA antibodies to allow for kidney transplantation.

Vonsetamig is being studied for treatment of patients in need of kidney transplantation who are highly sensitized to HLA.

The study is looking at several other research questions, including:

  • Side effects that may be experienced from taking vonsetamig
  • How vonsetamig works in the body
  • How much vonsetamig is present in the blood
  • If vonsetamig works to lower levels of antibodies to HLA
03

Conditions studied

  • Chronic Kidney Disease (CKD)

Keywords

  • Kidney Transplant
  • Hemodialysis
  • Desensitization
  • Human Leukocyte Antigen (HLA)
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Has Chronic Kidney Disease (CKD) requiring hemodialysis, and awaiting kidney transplant on the United Network for Organ Sharing (UNOS), with a cPRA ≥99.9%, or those with a cPRA >98% (98.1% to 99.8%) who have spent 5 years or longer on the waitlist, as defined in the protocol
  2. Adequate hematologic and adequate hepatic function as defined in the protocol
  3. Willing and able to comply with clinic visits and study-related procedures

Key Exclusion Criteria:

  1. Current or active not in remission for at least 1 year
  2. Central nervous system (CNS) pathology or history of CNS neurodegenerative or movement disorders
  3. Patients who have had their spleen removed, including patients with functional asplenia
  4. Patients who have received a stem cell transplantation within 5 years
  5. Use of agents within 8 weeks or 5 half-lives of study drug administration (whichever is larger)
  6. Total plasma IgG \<300 mg/dL at screening
  7. Continuous systemic treatment with more than 10 mg per day of prednisone (or anti-inflammatory equivalent) within 72 hours of start of study drug administration
  8. Received a calcineurin inhibitor (eg, tacrolimus, cyclosporine) within 30 days of study drug administration
  9. Received cyclophosphamide, rituximab, obinutuzumab, other anti-CD20 or B cell-depleting agents, or proteasome inhibitors or anti-CD38 therapies (eg, isatuximab, daratumumab) within 12 months of study drug administration
  10. Prior treatment with any anti-BCMA antibody (including antibody drug conjugate or bsAb) or BCMA-directed CAR-T cell therapy, as described in the protocol
  11. Has received a COVID-19 vaccination, as described in the protocol

Note: Other protocol defined inclusion / exclusion criteria apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Vonsetamig

    Drug: Vonsetamig

Interventions

  • Administered by intravenous (IV) infusion

    Also known as: BCMAxCD3, REGN5459

06

What researchers measure

Primary outcomes

  1. Incidence of adverse event(s) of interest (AEI) from the first dose through end of the safety observation period

    Time frame: Up to approximately 6 weeks

  2. Incidence and severity of treatment-emergent adverse events (TEAE)s from the first study drug dose up to the end of the study

    TEAEs include adverse events of special interest (AESI) and serious adverse events (SAEs)

    Time frame: Up to 78 weeks

Secondary outcomes

  1. Proportion of Participants with a clinically meaningful reduction in anti-HLA alloantibodies

    Clinically meaningful reduction in anti-HLA alloantibodies are defined as either: * Reduction in Calculated panel-reactive antibody (cPRA) from baseline, or * Reduction in the peak (immunodominant) anti-HLA mean fluorescence intensity (MFI) to \<5,000, or by ≥50% by Single antigen bead (SAB) assay

    Time frame: Up to 78 weeks

  2. Maximum reduction in the peak (immunodominant) MFI of anti-HLA alloantibodies from baseline

    Time frame: Up to 78 weeks

  3. Percent change from baseline in the peak (immunodominant) MFI

    Time frame: Up to 78 weeks

  4. Percent change from baseline in the sum of MFI of anti-HLA alloantibodies using the SAB assay

    Time frame: Up to 78 weeks

  5. Time to first clinically meaningful reduction in anti-HLA alloantibody levels by SAB assay

    Defined as peak anti-HLA alloantibody MFI \<5,000 or ≥50% reduction

    Time frame: Up to 78 weeks

  6. Time to maximal reduction in anti-HLA alloantibody levels by SAB assay

    Defined as peak anti-HLA alloantibody MFI \<5,000 or ≥50% reduction

    Time frame: Up to 78 weeks

  7. Maximum reduction in cPRA from baseline

    Time frame: Up to 78 weeks

  8. Time to first clinically meaningful reduction in cPRA

    Time frame: Up to 78 weeks

  9. Time to maximal reduction in cPRA from baseline

    Time frame: Up to 78 weeks

  10. Duration of a reduction in peak anti-HLA alloantibody to MFI <5,000 or by ≥50% by SAB assay

    Time frame: Up to 78 weeks

  11. Duration of maximal reduction in anti-HLA alloantibody MFI by SAB assay

    Time frame: Up to 78 weeks

  12. Duration of maximal reduction in cPRA by SAB assay

    Time frame: Up to 78 weeks

  13. Serum concentration of Immunoglobulin (Ig) classes over time

    Time frame: Up to 78 weeks

  14. Percent change from baseline of serum concentration of Ig classes

    Time frame: Up to 78 weeks

  15. Concentration of vonsetamig in serum over time

    Time frame: Up to 78 weeks

  16. Incidence of treatment-emergent anti-drug antibodies (ADAs) to vonsetamig over time

    Time frame: Up to 78 weeks

07

Study locations

10 sites
08

References and documents

Publications

  • Karam S, Boudhabhay I, Jhaveri KD. Bispecific Antibodies for Glomerular Diseases: Are We Ready for Prime Time? J Am Soc Nephrol. 2026 Apr 14. doi: 10.1681/ASN.0000001120. Online ahead of print. No abstract available. PubMed 41979896 ↗

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Nov 2027, 63 months after the start.

Of 22 phase 1/2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 63 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2021
First posted
Oct 25, 2021
StartActual
Aug 2, 2022
Primary completionEst.
Nov 22, 2027
CompletionEst.
Nov 22, 2027
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05092347
Responsible party
Sponsor
First posted
Oct 25, 2021
Start date
Aug 2, 2022
Primary completion
Nov 22, 2027 (estimated)
Completion
Nov 22, 2027 (estimated)
Last update
Jun 2, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonsetamig

Start the discussion